歌禮制藥(01672.HK)THR-BETA受體激動劑非酒精性脂肪性肝炎藥ASC41臨試申請獲批
格隆匯5月13日丨歌禮制藥-B(01672.HK)發佈公告,公司內部研發的一類藥ASC41已獲得國家藥品監督管理局(“NMPA”)批准進行非酒精性脂肪性肝炎(NASH)適應症的臨牀試驗(IND)。
公司的NASH管線中有另外兩款在研藥物:處於臨牀試驗II期的ASC40以及一款IND前在研藥物。ASC41有望單獨使用或與ASC40或IND前在研藥物聯合使用。ASC41是一款口服甲狀腺激素β受體(THR-beta)激動劑,而ASC40則是一款口服脂肪酸合成酶(FASN)抑制劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.